nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A7—Ifosfamide—testicular cancer	0.0824	0.173	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0824	0.173	CbGbCtD
Sirolimus—CYP3A5—Ifosfamide—testicular cancer	0.0618	0.13	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—testicular cancer	0.0444	0.093	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—testicular cancer	0.0341	0.0714	CbGbCtD
Sirolimus—CYP3A5—Etoposide—testicular cancer	0.0296	0.062	CbGbCtD
Sirolimus—CYP3A4—Ifosfamide—testicular cancer	0.0241	0.0505	CbGbCtD
Sirolimus—ABCB1—Vinblastine—testicular cancer	0.0214	0.0448	CbGbCtD
Sirolimus—ABCB1—Cisplatin—testicular cancer	0.0196	0.041	CbGbCtD
Sirolimus—ABCB1—Etoposide—testicular cancer	0.0192	0.0403	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—testicular cancer	0.0131	0.0275	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—testicular cancer	0.0128	0.0268	CbGbCtD
Sirolimus—ABCB1—Methotrexate—testicular cancer	0.0127	0.0266	CbGbCtD
Sirolimus—CYP3A4—Etoposide—testicular cancer	0.0115	0.0242	CbGbCtD
Sirolimus—EIF4E—embryo—testicular cancer	0.0097	0.144	CbGeAlD
Sirolimus—CYP3A4—Doxorubicin—testicular cancer	0.00786	0.0165	CbGbCtD
Sirolimus—EIF4E—gonad—testicular cancer	0.00659	0.098	CbGeAlD
Sirolimus—EIF4E—testis—testicular cancer	0.00475	0.0706	CbGeAlD
Sirolimus—MTOR—embryo—testicular cancer	0.00375	0.0558	CbGeAlD
Sirolimus—MTOR—seminal vesicle—testicular cancer	0.00353	0.0525	CbGeAlD
Sirolimus—FGF2—female gonad—testicular cancer	0.00326	0.0485	CbGeAlD
Sirolimus—FKBP1A—seminal vesicle—testicular cancer	0.00317	0.0472	CbGeAlD
Sirolimus—FGF2—testis—testicular cancer	0.00289	0.0431	CbGeAlD
Sirolimus—SLC47A1—seminal vesicle—testicular cancer	0.00273	0.0405	CbGeAlD
Sirolimus—MTOR—gonad—testicular cancer	0.00255	0.0379	CbGeAlD
Sirolimus—FKBP1A—gonad—testicular cancer	0.00229	0.0341	CbGeAlD
Sirolimus—FGF2—lymph node—testicular cancer	0.0021	0.0312	CbGeAlD
Sirolimus—MTOR—female gonad—testicular cancer	0.00207	0.0308	CbGeAlD
Sirolimus—SLC47A1—gonad—testicular cancer	0.00197	0.0293	CbGeAlD
Sirolimus—FKBP1A—female gonad—testicular cancer	0.00186	0.0277	CbGeAlD
Sirolimus—MTOR—testis—testicular cancer	0.00184	0.0273	CbGeAlD
Sirolimus—FKBP1A—testis—testicular cancer	0.00165	0.0246	CbGeAlD
Sirolimus—SLC47A1—female gonad—testicular cancer	0.0016	0.0238	CbGeAlD
Sirolimus—SLC47A1—testis—testicular cancer	0.00142	0.0211	CbGeAlD
Sirolimus—MTOR—lymph node—testicular cancer	0.00133	0.0198	CbGeAlD
Sirolimus—FKBP1A—lymph node—testicular cancer	0.0012	0.0178	CbGeAlD
Sirolimus—SLC47A1—lymph node—testicular cancer	0.00103	0.0153	CbGeAlD
Sirolimus—CYP3A5—female gonad—testicular cancer	0.000811	0.0121	CbGeAlD
Sirolimus—ABCB1—embryo—testicular cancer	0.000781	0.0116	CbGeAlD
Sirolimus—ABCB1—seminal vesicle—testicular cancer	0.000734	0.0109	CbGeAlD
Sirolimus—FGF2—PI3K Cascade—FGFR3—testicular cancer	0.000705	0.00468	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—KITLG—testicular cancer	0.000691	0.00459	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—KITLG—testicular cancer	0.000686	0.00456	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—BCL10—testicular cancer	0.000677	0.0045	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00067	0.00445	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—STK11—testicular cancer	0.000669	0.00444	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—STK11—testicular cancer	0.000636	0.00423	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—STK11—testicular cancer	0.000619	0.00411	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000618	0.0041	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.000613	0.00408	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—STK11—testicular cancer	0.000597	0.00397	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—STK11—testicular cancer	0.000597	0.00397	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000592	0.00393	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—FGFR3—testicular cancer	0.00059	0.00392	CbGpPWpGaD
Sirolimus—FGF2—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.000584	0.00388	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.000583	0.00388	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events—FGFR3—testicular cancer	0.000574	0.00381	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.000569	0.00378	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000569	0.00378	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—DNMT3L—testicular cancer	0.000555	0.00369	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—FGFR3—testicular cancer	0.000554	0.00368	CbGpPWpGaD
Sirolimus—FGF2—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000554	0.00368	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000543	0.00361	CbGpPWpGaD
Sirolimus—FGF2—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000536	0.00356	CbGpPWpGaD
Sirolimus—ABCB1—gonad—testicular cancer	0.00053	0.00789	CbGeAlD
Sirolimus—FGF2—Signaling by SCF-KIT—KITLG—testicular cancer	0.000529	0.00352	CbGpPWpGaD
Sirolimus—FGF2—PI-3K cascade—FGFR3—testicular cancer	0.000526	0.0035	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—KITLG—testicular cancer	0.000526	0.00349	CbGpPWpGaD
Sirolimus—MTOR—PI3K Cascade—FGFR3—testicular cancer	0.000523	0.00348	CbGpPWpGaD
Sirolimus—FGF2—Neural Crest Differentiation—FGFR3—testicular cancer	0.000514	0.00341	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—FGFR3—testicular cancer	0.000514	0.00341	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—KITLG—testicular cancer	0.000513	0.00341	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—FGFR3—testicular cancer	0.00051	0.00339	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—KITLG—testicular cancer	0.000509	0.00338	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000507	0.00336	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—BCL10—testicular cancer	0.000503	0.00334	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—KITLG—testicular cancer	0.000498	0.00331	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000498	0.00331	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.000497	0.0033	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—STK11—testicular cancer	0.000496	0.0033	CbGpPWpGaD
Sirolimus—FGF2—PI-3K cascade—KIT—testicular cancer	0.000483	0.00321	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—KITLG—testicular cancer	0.000476	0.00316	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—KITLG—testicular cancer	0.000474	0.00315	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—KIT—testicular cancer	0.000472	0.00313	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—KITLG—testicular cancer	0.000471	0.00313	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—KITLG—testicular cancer	0.000469	0.00312	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—KIT—testicular cancer	0.000468	0.00311	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000462	0.00307	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—FGFR3—testicular cancer	0.00046	0.00305	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000457	0.00304	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000449	0.00298	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—KITLG—testicular cancer	0.000441	0.00293	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—KITLG—testicular cancer	0.000441	0.00293	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000441	0.00293	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—FGFR3—testicular cancer	0.000438	0.00291	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—KITLG—testicular cancer	0.000437	0.00291	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.000434	0.00288	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000433	0.00288	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—KITLG—testicular cancer	0.000432	0.00287	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000431	0.00286	CbGpPWpGaD
Sirolimus—ABCB1—female gonad—testicular cancer	0.000431	0.00641	CbGeAlD
Sirolimus—MTOR—IRS-related events—FGFR3—testicular cancer	0.000426	0.00283	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000422	0.0028	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000411	0.00273	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—FGFR3—testicular cancer	0.000411	0.00273	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—KITLG—testicular cancer	0.000408	0.00271	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000402	0.00267	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000398	0.00264	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—INSL3—testicular cancer	0.000394	0.00262	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000393	0.00261	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—HPGDS—testicular cancer	0.000393	0.00261	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KITLG—testicular cancer	0.000393	0.00261	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000391	0.0026	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—FGFR3—testicular cancer	0.000391	0.00259	CbGpPWpGaD
Sirolimus—ABCB1—testis—testicular cancer	0.000382	0.00568	CbGeAlD
Sirolimus—MTOR—PI3K/AKT activation—FGFR3—testicular cancer	0.000381	0.00253	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—FGFR3—testicular cancer	0.000378	0.00251	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000376	0.0025	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000376	0.0025	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000376	0.0025	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—FGFR3—testicular cancer	0.00037	0.00246	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KITLG—testicular cancer	0.00037	0.00246	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00037	0.00246	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—KIT—testicular cancer	0.000361	0.0024	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—KIT—testicular cancer	0.000359	0.00238	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—FGFR3—testicular cancer	0.000354	0.00235	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KITLG—testicular cancer	0.000353	0.00235	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—FGFR3—testicular cancer	0.000352	0.00234	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KITLG—testicular cancer	0.000352	0.00234	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—FGFR3—testicular cancer	0.00035	0.00233	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—KIT—testicular cancer	0.00035	0.00233	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KITLG—testicular cancer	0.00035	0.00232	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—FGFR3—testicular cancer	0.000349	0.00232	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KITLG—testicular cancer	0.000348	0.00231	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—KIT—testicular cancer	0.000347	0.00231	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000346	0.0023	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000344	0.00228	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000343	0.00228	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000341	0.00227	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—KIT—testicular cancer	0.00034	0.00226	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000339	0.00225	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—FGFR3—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KITLG—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KITLG—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—FGFR3—testicular cancer	0.000325	0.00216	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—KIT—testicular cancer	0.000325	0.00216	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KITLG—testicular cancer	0.000325	0.00216	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—KIT—testicular cancer	0.000323	0.00215	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000322	0.00214	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000322	0.00214	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—KIT—testicular cancer	0.000322	0.00214	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—FGFR3—testicular cancer	0.000321	0.00213	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KITLG—testicular cancer	0.00032	0.00213	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—KIT—testicular cancer	0.00032	0.00213	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000315	0.0021	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—FGFR3—testicular cancer	0.000304	0.00202	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KITLG—testicular cancer	0.000303	0.00201	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—KIT—testicular cancer	0.000301	0.002	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000301	0.002	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—KIT—testicular cancer	0.000301	0.002	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KITLG—testicular cancer	0.000301	0.002	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—KIT—testicular cancer	0.000298	0.00198	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—BCL10—testicular cancer	0.000298	0.00198	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000296	0.00196	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—KIT—testicular cancer	0.000294	0.00196	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000292	0.00194	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000291	0.00193	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00029	0.00193	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—INSL3—testicular cancer	0.000289	0.00192	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—HPGDS—testicular cancer	0.000284	0.00189	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—BCL10—testicular cancer	0.000284	0.00189	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000279	0.00186	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—KIT—testicular cancer	0.000279	0.00185	CbGpPWpGaD
Sirolimus—ABCB1—lymph node—testicular cancer	0.000277	0.00412	CbGeAlD
Sirolimus—MTOR—Signaling by ERBB4—FGFR3—testicular cancer	0.000275	0.00183	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—BCL10—testicular cancer	0.000273	0.00181	CbGpPWpGaD
Sirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000269	0.00179	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KIT—testicular cancer	0.000268	0.00178	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000267	0.00177	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—FGFR3—testicular cancer	0.000263	0.00174	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—FGFR3—testicular cancer	0.000261	0.00174	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—FGFR3—testicular cancer	0.00026	0.00173	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—FGFR3—testicular cancer	0.000259	0.00172	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—H2AFZ—testicular cancer	0.000259	0.00172	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000256	0.0017	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000255	0.00169	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KIT—testicular cancer	0.000252	0.00168	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—FGFR3—testicular cancer	0.000243	0.00162	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000243	0.00162	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000243	0.00162	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—FGFR3—testicular cancer	0.000241	0.0016	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KIT—testicular cancer	0.000241	0.0016	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KIT—testicular cancer	0.00024	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000239	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KIT—testicular cancer	0.000239	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—FGFR3—testicular cancer	0.000238	0.00158	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KIT—testicular cancer	0.000238	0.00158	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000234	0.00156	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—FGFR3—testicular cancer	0.000225	0.0015	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000223	0.00148	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KIT—testicular cancer	0.000223	0.00148	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KIT—testicular cancer	0.000223	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—FGFR3—testicular cancer	0.000223	0.00148	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KITLG—testicular cancer	0.000223	0.00148	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KIT—testicular cancer	0.000221	0.00147	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00022	0.00146	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—INSL3—testicular cancer	0.000219	0.00146	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KIT—testicular cancer	0.000219	0.00145	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—BCL10—testicular cancer	0.000211	0.0014	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KIT—testicular cancer	0.000207	0.00137	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KIT—testicular cancer	0.000205	0.00136	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—BCL10—testicular cancer	0.000203	0.00135	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000198	0.00131	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000197	0.00131	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—H2AFZ—testicular cancer	0.000194	0.00129	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP2—testicular cancer	0.000194	0.00129	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KITLG—testicular cancer	0.00018	0.00119	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KITLG—testicular cancer	0.000171	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—FGFR3—testicular cancer	0.000166	0.0011	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL10—testicular cancer	0.000166	0.0011	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KITLG—testicular cancer	0.000165	0.00109	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000165	0.00109	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—MMP2—testicular cancer	0.000163	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INSL3—testicular cancer	0.000163	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KIT—testicular cancer	0.000152	0.00101	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000143	0.000952	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—FGFR3—testicular cancer	0.000134	0.000887	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—H2AFZ—testicular cancer	0.000132	0.000878	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000132	0.000878	CbGpPWpGaD
Sirolimus—Sweating—Epirubicin—testicular cancer	0.000129	0.000422	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—testicular cancer	0.000129	0.000422	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—testicular cancer	0.000128	0.00042	CcSEcCtD
Sirolimus—Dizziness—Ifosfamide—testicular cancer	0.000128	0.000419	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—testicular cancer	0.000128	0.000419	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—FGFR3—testicular cancer	0.000127	0.000846	CbGpPWpGaD
Sirolimus—Urinary tract disorder—Methotrexate—testicular cancer	0.000127	0.000417	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—KITLG—testicular cancer	0.000127	0.000845	CbGpPWpGaD
Sirolimus—Hepatobiliary disease—Epirubicin—testicular cancer	0.000127	0.000416	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—testicular cancer	0.000127	0.000416	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—testicular cancer	0.000127	0.000415	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—testicular cancer	0.000126	0.000414	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—H2AFZ—testicular cancer	0.000126	0.000839	CbGpPWpGaD
Sirolimus—Weight decreased—Doxorubicin—testicular cancer	0.000126	0.000413	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—testicular cancer	0.000126	0.000413	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—testicular cancer	0.000126	0.000413	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—testicular cancer	0.000126	0.000412	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—STK11—testicular cancer	0.000126	0.000834	CbGpPWpGaD
Sirolimus—Nausea—Dactinomycin—testicular cancer	0.000125	0.000411	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—testicular cancer	0.000125	0.00041	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—testicular cancer	0.000125	0.00041	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—testicular cancer	0.000124	0.000407	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—testicular cancer	0.000124	0.000407	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—testicular cancer	0.000124	0.000407	CcSEcCtD
Sirolimus—Vomiting—Ifosfamide—testicular cancer	0.000123	0.000403	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—testicular cancer	0.000123	0.000403	CcSEcCtD
Sirolimus—MTOR—Immune System—BCL10—testicular cancer	0.000123	0.000816	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KIT—testicular cancer	0.000123	0.000814	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—FGFR3—testicular cancer	0.000122	0.000813	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KITLG—testicular cancer	0.000122	0.000812	CbGpPWpGaD
Sirolimus—Rash—Ifosfamide—testicular cancer	0.000122	0.0004	CcSEcCtD
Sirolimus—Dermatitis—Ifosfamide—testicular cancer	0.000122	0.0004	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000122	0.000399	CcSEcCtD
Sirolimus—FKBP1A—Disease—KITLG—testicular cancer	0.000122	0.000808	CbGpPWpGaD
Sirolimus—Haemoglobin—Epirubicin—testicular cancer	0.000121	0.000397	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—testicular cancer	0.000121	0.000397	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—testicular cancer	0.000121	0.000396	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—testicular cancer	0.000121	0.000396	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—testicular cancer	0.000121	0.000396	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—testicular cancer	0.000121	0.000396	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—testicular cancer	0.000121	0.000396	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—testicular cancer	0.000121	0.000395	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—testicular cancer	0.00012	0.000394	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—testicular cancer	0.00012	0.000393	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—testicular cancer	0.00012	0.000392	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—testicular cancer	0.00012	0.000392	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—testicular cancer	0.00012	0.000392	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—testicular cancer	0.000119	0.000391	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—testicular cancer	0.000119	0.00039	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—testicular cancer	0.000119	0.000389	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—testicular cancer	0.000119	0.000388	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—testicular cancer	0.000119	0.000388	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—testicular cancer	0.000118	0.000387	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000118	0.000385	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—MMP2—testicular cancer	0.000117	0.00078	CbGpPWpGaD
Sirolimus—Epistaxis—Doxorubicin—testicular cancer	0.000117	0.000384	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—KIT—testicular cancer	0.000117	0.000777	CbGpPWpGaD
Sirolimus—Angiopathy—Methotrexate—testicular cancer	0.000117	0.000383	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—testicular cancer	0.000117	0.000382	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—testicular cancer	0.000116	0.000382	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—testicular cancer	0.000116	0.000381	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—testicular cancer	0.000116	0.000381	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—KITLG—testicular cancer	0.000116	0.000772	CbGpPWpGaD
Sirolimus—Chills—Methotrexate—testicular cancer	0.000116	0.000379	CcSEcCtD
Sirolimus—Nausea—Ifosfamide—testicular cancer	0.000115	0.000377	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—testicular cancer	0.000114	0.000374	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—testicular cancer	0.000113	0.000369	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—testicular cancer	0.000112	0.000369	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—KIT—testicular cancer	0.000112	0.000746	CbGpPWpGaD
Sirolimus—Malnutrition—Methotrexate—testicular cancer	0.000112	0.000368	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—testicular cancer	0.000112	0.000368	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—testicular cancer	0.000112	0.000367	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—testicular cancer	0.000112	0.000367	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—testicular cancer	0.000112	0.000366	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—testicular cancer	0.000111	0.000364	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—testicular cancer	0.000111	0.000363	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—testicular cancer	0.00011	0.000361	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—testicular cancer	0.00011	0.00036	CcSEcCtD
Sirolimus—Asthenia—Etoposide—testicular cancer	0.00011	0.000359	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—testicular cancer	0.00011	0.000359	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—testicular cancer	0.000109	0.000359	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—testicular cancer	0.000109	0.000359	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—testicular cancer	0.000109	0.000357	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—testicular cancer	0.000109	0.000356	CcSEcCtD
Sirolimus—Back pain—Methotrexate—testicular cancer	0.000109	0.000356	CcSEcCtD
Sirolimus—Chills—Epirubicin—testicular cancer	0.000108	0.000355	CcSEcCtD
Sirolimus—Pruritus—Etoposide—testicular cancer	0.000108	0.000354	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—testicular cancer	0.000108	0.000352	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—testicular cancer	0.000106	0.000348	CcSEcCtD
Sirolimus—Rash—Cisplatin—testicular cancer	0.000105	0.000345	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—testicular cancer	0.000105	0.000344	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—testicular cancer	0.000105	0.000344	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—testicular cancer	0.000105	0.000343	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—testicular cancer	0.000104	0.000341	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—testicular cancer	0.000104	0.000341	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—testicular cancer	0.000104	0.00034	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—testicular cancer	0.000104	0.000339	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—testicular cancer	0.000103	0.000339	CcSEcCtD
Sirolimus—Tension—Epirubicin—testicular cancer	0.000103	0.000338	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—testicular cancer	0.000102	0.000334	CcSEcCtD
Sirolimus—Back pain—Epirubicin—testicular cancer	0.000102	0.000333	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—testicular cancer	0.000101	0.000332	CcSEcCtD
Sirolimus—Malaise—Methotrexate—testicular cancer	0.000101	0.000332	CcSEcCtD
Sirolimus—Dizziness—Etoposide—testicular cancer	0.000101	0.000331	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—testicular cancer	0.000101	0.000331	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—testicular cancer	0.000101	0.00033	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—testicular cancer	0.000101	0.00033	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—testicular cancer	0.0001	0.000329	CcSEcCtD
Sirolimus—FGF2—Disease—H2AFZ—testicular cancer	0.0001	0.000666	CbGpPWpGaD
Sirolimus—Chills—Doxorubicin—testicular cancer	0.0001	0.000328	CcSEcCtD
Sirolimus—FGF2—Immune System—KITLG—testicular cancer	9.99e-05	0.000663	CbGpPWpGaD
Sirolimus—Nausea—Cisplatin—testicular cancer	9.91e-05	0.000325	CcSEcCtD
Sirolimus—Cough—Methotrexate—testicular cancer	9.79e-05	0.000321	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—testicular cancer	9.74e-05	0.000319	CcSEcCtD
Sirolimus—Vomiting—Etoposide—testicular cancer	9.72e-05	0.000319	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—testicular cancer	9.72e-05	0.000318	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—testicular cancer	9.7e-05	0.000318	CcSEcCtD
Sirolimus—Agitation—Epirubicin—testicular cancer	9.65e-05	0.000316	CcSEcCtD
Sirolimus—Rash—Etoposide—testicular cancer	9.64e-05	0.000316	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—testicular cancer	9.63e-05	0.000316	CcSEcCtD
Sirolimus—Headache—Etoposide—testicular cancer	9.58e-05	0.000314	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—testicular cancer	9.57e-05	0.000314	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—testicular cancer	9.55e-05	0.000313	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—testicular cancer	9.55e-05	0.000313	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—testicular cancer	9.55e-05	0.000313	CcSEcCtD
Sirolimus—Tension—Doxorubicin—testicular cancer	9.53e-05	0.000312	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	9.49e-05	0.000311	CcSEcCtD
Sirolimus—Malaise—Epirubicin—testicular cancer	9.47e-05	0.00031	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—FGFR3—testicular cancer	9.46e-05	0.000628	CbGpPWpGaD
Sirolimus—Discomfort—Methotrexate—testicular cancer	9.44e-05	0.000309	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—testicular cancer	9.44e-05	0.000309	CcSEcCtD
Sirolimus—Syncope—Epirubicin—testicular cancer	9.42e-05	0.000309	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—testicular cancer	9.4e-05	0.000308	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—testicular cancer	9.4e-05	0.000308	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—testicular cancer	9.34e-05	0.000306	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—testicular cancer	9.28e-05	0.000304	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—H2AFZ—testicular cancer	9.26e-05	0.000615	CbGpPWpGaD
Sirolimus—Confusional state—Methotrexate—testicular cancer	9.23e-05	0.000303	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—testicular cancer	9.23e-05	0.000302	CcSEcCtD
Sirolimus—FGF2—Disease—KITLG—testicular cancer	9.22e-05	0.000612	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STK11—testicular cancer	9.21e-05	0.000612	CbGpPWpGaD
Sirolimus—Cough—Epirubicin—testicular cancer	9.16e-05	0.0003	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—testicular cancer	9.16e-05	0.0003	CcSEcCtD
Sirolimus—Infection—Methotrexate—testicular cancer	9.1e-05	0.000298	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—FGFR3—testicular cancer	9.08e-05	0.000603	CbGpPWpGaD
Sirolimus—Nausea—Etoposide—testicular cancer	9.08e-05	0.000298	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—testicular cancer	9.07e-05	0.000297	CcSEcCtD
Sirolimus—FKBP1A—Disease—FGFR3—testicular cancer	9.04e-05	0.000601	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Doxorubicin—testicular cancer	9.01e-05	0.000295	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—testicular cancer	8.98e-05	0.000294	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—testicular cancer	8.98e-05	0.000294	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—testicular cancer	8.97e-05	0.000294	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—testicular cancer	8.94e-05	0.000293	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—testicular cancer	8.94e-05	0.000293	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—testicular cancer	8.94e-05	0.000293	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—testicular cancer	8.93e-05	0.000293	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—testicular cancer	8.91e-05	0.000292	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—testicular cancer	8.89e-05	0.000291	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	8.88e-05	0.000291	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—testicular cancer	8.85e-05	0.00029	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—testicular cancer	8.83e-05	0.000289	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—testicular cancer	8.76e-05	0.000287	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—testicular cancer	8.73e-05	0.000286	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—testicular cancer	8.71e-05	0.000286	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—testicular cancer	8.7e-05	0.000285	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—KIT—testicular cancer	8.68e-05	0.000577	CbGpPWpGaD
Sirolimus—Confusional state—Epirubicin—testicular cancer	8.64e-05	0.000283	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—FGFR3—testicular cancer	8.63e-05	0.000573	CbGpPWpGaD
Sirolimus—Palpitations—Doxorubicin—testicular cancer	8.59e-05	0.000281	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—testicular cancer	8.57e-05	0.000281	CcSEcCtD
Sirolimus—Oedema—Epirubicin—testicular cancer	8.57e-05	0.000281	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—testicular cancer	8.56e-05	0.00028	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—testicular cancer	8.54e-05	0.00028	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—KITLG—testicular cancer	8.52e-05	0.000566	CbGpPWpGaD
Sirolimus—Infection—Epirubicin—testicular cancer	8.51e-05	0.000279	CcSEcCtD
Sirolimus—Cough—Doxorubicin—testicular cancer	8.48e-05	0.000278	CcSEcCtD
Sirolimus—Shock—Epirubicin—testicular cancer	8.43e-05	0.000276	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—testicular cancer	8.4e-05	0.000275	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—testicular cancer	8.39e-05	0.000275	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—testicular cancer	8.39e-05	0.000275	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—testicular cancer	8.36e-05	0.000274	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.34e-05	0.000273	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—KIT—testicular cancer	8.34e-05	0.000554	CbGpPWpGaD
Sirolimus—Skin disorder—Epirubicin—testicular cancer	8.32e-05	0.000273	CcSEcCtD
Sirolimus—FKBP1A—Disease—KIT—testicular cancer	8.3e-05	0.000551	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Epirubicin—testicular cancer	8.28e-05	0.000271	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—testicular cancer	8.28e-05	0.000271	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—testicular cancer	8.27e-05	0.000271	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—testicular cancer	8.27e-05	0.000271	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—testicular cancer	8.27e-05	0.000271	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—testicular cancer	8.24e-05	0.00027	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—testicular cancer	8.22e-05	0.000269	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.21e-05	0.000269	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—testicular cancer	8.17e-05	0.000268	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—testicular cancer	8.17e-05	0.000268	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—testicular cancer	8.16e-05	0.000268	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—testicular cancer	8.14e-05	0.000267	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—testicular cancer	8.06e-05	0.000264	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—testicular cancer	8.01e-05	0.000262	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—testicular cancer	7.99e-05	0.000262	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—testicular cancer	7.96e-05	0.000261	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—testicular cancer	7.93e-05	0.00026	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—testicular cancer	7.93e-05	0.00026	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—KIT—testicular cancer	7.93e-05	0.000526	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Methotrexate—testicular cancer	7.91e-05	0.000259	CcSEcCtD
Sirolimus—Infection—Doxorubicin—testicular cancer	7.88e-05	0.000258	CcSEcCtD
Sirolimus—Pain—Methotrexate—testicular cancer	7.83e-05	0.000257	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—testicular cancer	7.81e-05	0.000256	CcSEcCtD
Sirolimus—Shock—Doxorubicin—testicular cancer	7.8e-05	0.000256	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—testicular cancer	7.78e-05	0.000255	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—testicular cancer	7.76e-05	0.000254	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—testicular cancer	7.75e-05	0.000254	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—testicular cancer	7.74e-05	0.000254	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—testicular cancer	7.7e-05	0.000252	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—testicular cancer	7.69e-05	0.000252	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—testicular cancer	7.67e-05	0.000251	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—testicular cancer	7.64e-05	0.00025	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—testicular cancer	7.62e-05	0.00025	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—testicular cancer	7.56e-05	0.000248	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—testicular cancer	7.55e-05	0.000247	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—testicular cancer	7.54e-05	0.000247	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—testicular cancer	7.49e-05	0.000245	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—testicular cancer	7.45e-05	0.000244	CcSEcCtD
Sirolimus—MTOR—Disease—H2AFZ—testicular cancer	7.44e-05	0.000494	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FGFR3—testicular cancer	7.42e-05	0.000493	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KITLG—testicular cancer	7.41e-05	0.000492	CbGpPWpGaD
Sirolimus—Hypotension—Doxorubicin—testicular cancer	7.41e-05	0.000243	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—testicular cancer	7.4e-05	0.000242	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—HPGDS—testicular cancer	7.33e-05	0.000487	CbGpPWpGaD
Sirolimus—Constipation—Epirubicin—testicular cancer	7.33e-05	0.00024	CcSEcCtD
Sirolimus—Pain—Epirubicin—testicular cancer	7.33e-05	0.00024	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—testicular cancer	7.24e-05	0.000237	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—testicular cancer	7.24e-05	0.000237	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.22e-05	0.000237	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—testicular cancer	7.17e-05	0.000235	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—testicular cancer	7.12e-05	0.000233	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—testicular cancer	7.07e-05	0.000232	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—testicular cancer	7.06e-05	0.000231	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—testicular cancer	7.05e-05	0.000231	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—H2AFZ—testicular cancer	7.02e-05	0.000466	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Epirubicin—testicular cancer	7.01e-05	0.00023	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—testicular cancer	6.98e-05	0.000229	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—STK11—testicular cancer	6.98e-05	0.000464	CbGpPWpGaD
Sirolimus—Decreased appetite—Doxorubicin—testicular cancer	6.89e-05	0.000226	CcSEcCtD
Sirolimus—FGF2—Disease—FGFR3—testicular cancer	6.85e-05	0.000455	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Doxorubicin—testicular cancer	6.85e-05	0.000224	CcSEcCtD
Sirolimus—MTOR—Disease—KITLG—testicular cancer	6.84e-05	0.000455	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIT—testicular cancer	6.81e-05	0.000453	CbGpPWpGaD
Sirolimus—Pain—Doxorubicin—testicular cancer	6.78e-05	0.000222	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—testicular cancer	6.78e-05	0.000222	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—testicular cancer	6.77e-05	0.000222	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—testicular cancer	6.77e-05	0.000222	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—testicular cancer	6.75e-05	0.000221	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—HPGDS—testicular cancer	6.73e-05	0.000447	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—testicular cancer	6.57e-05	0.000215	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—testicular cancer	6.53e-05	0.000214	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—testicular cancer	6.48e-05	0.000212	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—testicular cancer	6.48e-05	0.000212	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—KITLG—testicular cancer	6.46e-05	0.000429	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGFR3—testicular cancer	6.33e-05	0.000421	CbGpPWpGaD
Sirolimus—Hypersensitivity—Epirubicin—testicular cancer	6.31e-05	0.000207	CcSEcCtD
Sirolimus—FGF2—Disease—KIT—testicular cancer	6.29e-05	0.000418	CbGpPWpGaD
Sirolimus—Body temperature increased—Doxorubicin—testicular cancer	6.27e-05	0.000205	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—testicular cancer	6.27e-05	0.000205	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—testicular cancer	6.27e-05	0.000205	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—testicular cancer	6.15e-05	0.000201	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—testicular cancer	6.06e-05	0.000199	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—testicular cancer	6.06e-05	0.000198	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—testicular cancer	5.86e-05	0.000192	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—testicular cancer	5.84e-05	0.000191	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—testicular cancer	5.82e-05	0.000191	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—KIT—testicular cancer	5.81e-05	0.000386	CbGpPWpGaD
Sirolimus—Rash—Methotrexate—testicular cancer	5.77e-05	0.000189	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—testicular cancer	5.77e-05	0.000189	CcSEcCtD
Sirolimus—Headache—Methotrexate—testicular cancer	5.74e-05	0.000188	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—testicular cancer	5.69e-05	0.000186	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—testicular cancer	5.67e-05	0.000186	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—testicular cancer	5.61e-05	0.000184	CcSEcCtD
Sirolimus—MTOR—Immune System—FGFR3—testicular cancer	5.51e-05	0.000366	CbGpPWpGaD
Sirolimus—Vomiting—Epirubicin—testicular cancer	5.45e-05	0.000179	CcSEcCtD
Sirolimus—Nausea—Methotrexate—testicular cancer	5.44e-05	0.000178	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—testicular cancer	5.43e-05	0.000178	CcSEcCtD
Sirolimus—Rash—Epirubicin—testicular cancer	5.4e-05	0.000177	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—testicular cancer	5.4e-05	0.000177	CcSEcCtD
Sirolimus—Headache—Epirubicin—testicular cancer	5.37e-05	0.000176	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—STK11—testicular cancer	5.33e-05	0.000354	CbGpPWpGaD
Sirolimus—Dizziness—Doxorubicin—testicular cancer	5.24e-05	0.000172	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—H2AFZ—testicular cancer	5.21e-05	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STK11—testicular cancer	5.18e-05	0.000344	CbGpPWpGaD
Sirolimus—Nausea—Epirubicin—testicular cancer	5.09e-05	0.000167	CcSEcCtD
Sirolimus—MTOR—Disease—FGFR3—testicular cancer	5.09e-05	0.000338	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—testicular cancer	5.06e-05	0.000336	CbGpPWpGaD
Sirolimus—Vomiting—Doxorubicin—testicular cancer	5.04e-05	0.000165	CcSEcCtD
Sirolimus—Rash—Doxorubicin—testicular cancer	5e-05	0.000164	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—testicular cancer	4.99e-05	0.000164	CcSEcCtD
Sirolimus—Headache—Doxorubicin—testicular cancer	4.97e-05	0.000163	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—STK11—testicular cancer	4.89e-05	0.000325	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HPGDS—testicular cancer	4.86e-05	0.000323	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGFR3—testicular cancer	4.8e-05	0.000319	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KITLG—testicular cancer	4.79e-05	0.000318	CbGpPWpGaD
Sirolimus—Nausea—Doxorubicin—testicular cancer	4.71e-05	0.000154	CcSEcCtD
Sirolimus—MTOR—Disease—KIT—testicular cancer	4.67e-05	0.00031	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—testicular cancer	4.41e-05	0.000293	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HPGDS—testicular cancer	3.67e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—testicular cancer	3.56e-05	0.000237	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—STK11—testicular cancer	3.53e-05	0.000235	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—testicular cancer	3.27e-05	0.000217	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—STK11—testicular cancer	2.67e-05	0.000177	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPGDS—testicular cancer	2.26e-05	0.00015	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STK11—testicular cancer	1.64e-05	0.000109	CbGpPWpGaD
